Lilly cuts $1bn deal for Centrexion’s non-opioid painkiller

Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therap